Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Raised $83.6 million in gross proceeds from common stock offeringSTOPS™ and CAM programs: initial data presented at conferences, dosing in 2nd CHB cohorts ongoingClinical trial application filed for...
-
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
-
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common...
-
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of...
-
-First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients-Presentations include nonclinical data from 3 other CHB programs ...
-
-Five scientific posters to be presented at upcoming EASL ILC meeting- All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being...
-
Subjects experienced a 2.9 log10 IU/mL mean reduction in HBV DNA levels after 14 days’ dosing with 100 mg ALG-000184 Half (4 out of 8) of these subjects had HBV DNA levels below the lower limit of...
-
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...
-
SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...
-
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...